William Blair Has Pessimistic Outlook of TLX FY2027 Earnings

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Investment analysts at William Blair reduced their FY2027 earnings per share (EPS) estimates for shares of Telix Pharmaceuticals in a note issued to investors on Thursday, August 21st. William Blair analyst A. Hsieh now expects that the company will earn $0.49 per share for the year, down from their prior forecast of $0.58. William Blair has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share.

TLX has been the subject of a number of other reports. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th. HC Wainwright assumed coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They set a “buy” rating and a $23.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $22.33.

Telix Pharmaceuticals Stock Up 2.8%

Shares of NASDAQ TLX opened at $12.54 on Monday. The stock has a fifty day moving average price of $14.30 and a two-hundred day moving average price of $16.19. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. Telix Pharmaceuticals has a 1 year low of $10.50 and a 1 year high of $30.36.

Hedge Funds Weigh In On Telix Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Private Advisor Group LLC acquired a new position in shares of Telix Pharmaceuticals in the first quarter worth $170,000. ABC Arbitrage SA acquired a new position in Telix Pharmaceuticals during the first quarter worth $451,000. Russell Investments Group Ltd. acquired a new position in Telix Pharmaceuticals during the second quarter worth $975,000. Jane Street Group LLC acquired a new position in Telix Pharmaceuticals during the second quarter worth $564,000. Finally, IHT Wealth Management LLC acquired a new position in Telix Pharmaceuticals during the second quarter worth $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.